Request Meetings with US Companies
Profiles of attending companies are listed below. PLEASE CHECK THIS WEBSITE REGULARLY FOR AN UPDATED LIST.
The DEADLINE to submit your meeting requests is NOVEMBER 5, 2011.
THE PROCESS:
-
You will receive a confirmation email for each request made
-
UBIFRANCE will begin processing all meeting requests from November 5th, 2011, and will confirm mutual interest from the other party
-
A provisional schedule will be sent to you a few days before the event and a finalized schedule on the day of the event
If you have any questions about this process, please CONTACT US.
In order to improve your chances of meeting with the companies of your choice, make your meeting requests as specific, simple and direct as possible. Include information about what your company can offer and what your company is looking for.
Avanti Therapeutics
Fight the disease not the treatment
More ?
COMPANY :
We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life.
TECHNOLOGY :
Multifunctional nanoparticles for devloping and commercializing personalized medicine product pipelines
OBJECTIVES :
Find synergies with french companies to partner for joint development of products for neuroscience and inflammation.
COMPANY INFORMATION :
-
Address :20876 Germantown - Maryland
- Website :http://www.at-gc.com
Close
Biomedical Research Models
BIOMEDICAL RESEARCH MODELS, INC.
is dedicated to working in partnership with our customers to advance life science research by:
•Applying our unique expertise in animal studies,
•Specialty contract research, and
•The development of novel disease models.
More ?
COMPANY :
Biomedical Research Models, Inc. (“BRM”, “the Company”) is a University of Massachusetts biotechnology spin-off established in 1996 in Worcester, MA. BRM possesses proprietary genetic strains of rodents that are essential for the characterization of immune-related disease and the testing of new treatments for human immune diseases, including diabetes and neurodegenerative diseases. Its technical competencies are specific to immunology, neurology, inflammation and the husbandry of specialized, inbred rodent species. The Company has built a profitable contract research organization (“CRO”) business that has provided research support and experimentation services to the biopharmaceutical industry, the US Military, academia and the National Institutes of Health (“NIH”).
TECHNOLOGY :
Specialized, genetically inbred rodents and experimental services
BRM has additional inbred strains of proprietary rodents which are useful in studying other autoimmune disease including rheumatoid arthritis and multiple sclerosis. It also possesses rat strains which readily adopt humanized immune systems, enabling the study of cancer, transplantation other immune diseases and their treatments.
OBJECTIVES :
Establish a collaboration or research agreement with a pharm or biotech company.
COMPANY INFORMATION :
-
Address :67 Millbrook Street - 01606 Worcester - Ma
- Website :http://www.biomere.com
Close
Broad Institute of MIT & Harvard
The Broad Institute's mission is to propel the understanding and treatment of disease.
More ?
COMPANY :
The Broad Institute is especially active in: (i) discovering the molecular basis of disease, through genomics and mechanistic studies; and (ii) pioneering new chemistry-based approaches to developing probes and therapeutics for disease. Our primary therapeutic goals are to accelerate the discovery and development of novel therapies by: (i) developing powerful new approaches and processes for drug discovery and development; (ii) validating new biological pathways as relevant in disease; and (iii) expanding the universe of “druggable” targets Increasingly, the Broad community is generating a promising pipeline of novel drug discovery projects across a wide rage of therapeutic areas.
OBJECTIVES :
We are always interested in collaborations that would help translate novel scientific discoveries into successful therapeutics.
COMPANY INFORMATION :
-
Address :Cambridge - MA
- Website :http://www.broadinstitute.org/
Close
EUTHYMICS BIOSCIENCES
Euthymics is developing products for two central nervous system disorders of significant unmet medical needs: major depressive disorders and ADHD.
More ?
COMPANY :
Euthymics Bioscience is focused on developing therapeutics which help patients achieve euthymia.
COMPANY INFORMATION :
-
Address :43 Thorndike street Suite 1-3 Cambridge , MA 02141 - 02141 Cambridge - MA
- Website :http://www.euthymics.com
Close
Genosco
Genosco is three year old new Biotech company to discover and develop kinase inhibitor for the following diesase areas; inflammation (arhtritis), CNS disease and cancer.
More ?
COMPANY :
Our pipeline opportunities include selective inhibitors within signal networks of SYK, FLT3, and LRRK2. Our programs target a selective SYK inhibitor for rheumatoid arthritis, a selective FLT3 inhibitor for acute myeloid leukemia, as well as a LRRK2 selective inhibitor for the treatment of Parkinson’s disease. SYK lead candidate wil enter to preclinical study at Q4, 2011 and FLT3 lead at Q1, 2012. LRRK2 leads are in optimization stage.
OBJECTIVES :
We are looking for partner(s) to license out our SYK inhibitor lead as anti-rheumatoid arthritis and our FLT3 inhibitor lead as AML drug. We are also looking for a partner to strategically collaborate our LRRK2 program which already have several lead candidates with low single nM potency and x20 fold selectivity across several kinases (in-house) and good PK. We are going to test their in vivo efficay in our proprietary LRRK2 G2019S mouse model.
COMPANY INFORMATION :
-
Address :767C Concord Ave. - 02138 Cambridge - MA
- Website :http://www.genosco.com
Close
JB Therapeutics Inc.
Phase 2 non-psychotropic cannabinoid for the treatmente of diffuse Scleroderma
More ?
COMPANY :
JB Therapeuticsis a biopharmaceutical company developing ajuleimic acid, an oral non-psychotropic cannabinoid agonist for the treatment of life threatening autoimmune and fibrotic diseases.
TECHNOLOGY :
AJA is a synthetic nanomolar CB1/CB2 cannabinoid agonist structurally related to delta 9-THC, the active ingedient in marijuana. However, unlike THC, it is not pyschoative, having been chemically modified to minimize its passage through the blood brain barrier.
AJA has been shown in numerous in vitro and in vivo models to have potent anti-inflammatory, analgesic and anti-fibrotic activities. In a mouse SSc model AJA inhibited the development of skin & lung fibrosis and in a human SSc fibroblasts it reduced the production of extracellular matrix proteins & profibrotic cytokine-TGF-beta.
The company is now seeking to raise $funds to complete a phase 2 proof-of-concept clinical study in scleroderma.
OBJECTIVES :
We are looking for a partnership or option agreement to finance the completion of the phase 2 POC study in scleroderma.
COMPANY INFORMATION :
-
Address :508 Dudley Rd Suite 100 - 02459 Newton - MA
- Website :http://www.jbtherapeutics.com
Close
Johns Hopkins Technology Transfer
Translating the discoveries of the future.
More ?
COMPANY :
The Johns Hopkins Technology Transfer Office (JHTT) is the University’s intellectual property administration center, serving Johns Hopkins researchers and inventors as a licensing, patent, and technology commercialization office and acting as an active liaison to parties interested in leveraging JHU research or materials for academic or corporate endeavors.
The primary functions of JHTT include: (1) encouraging the disclosure of new ideas and discoveries and helping JHU researchers to identify patentable and copyrightable inventions and tangible research properties that might ultimately become commercial products and services; (2) protecting and managing the University's intellectual and tangible property; (3) licensing the University's technologies, facilitating collaborations between researchers, companies, and entrepreneurs interested in developing our innovations, and returning appropriate revenue to our laboratories; (4)
encouraging and supporting product development and entrepreneurial activities within the University; and (5) seeking and nurturing contacts with national and international companies and entrepreneurs that are capable of developing and commercializing our innovations for the public good.
OBJECTIVES :
Partnering and building connections.
COMPANY INFORMATION :
-
Address :100 North Charles Street, Suite 500 - 21201 Baltimore - Maryland
- Website :http://www.techtransfer.jhu.edu
Close
PharmaFacts
Pharmafacts is a pharmaceutical consulting and outsourcing management company providing resources to take your IP to IND.
More ?
COMPANY :
PharmaFacts is a global leader in the strategic planning of all facets of your late Discovery and Early Development Program. As IND-enablers... and more... we confidently and competently provide expert consulting on pre-clinical IND requirements (both biology and chemistry), whether it is
• Access to our pool of expert independent consultants – this consortium of individuals can cover most aspects of the IND-enabling space
• Project management and program development strategy
• PreIND submission - if appropriate
• IND compilation
• FDA support
• SBIR preparation
• Selection of CROs – we know the playing field. In your order of importance, i.e. pricing, specialty and speed of execution, we can help you with the best match
• Outsourcing oversight - helping you to piece together this complex process.
• Study design, protocol and report review
Our extensive knowledge of CROs enables us to provide expert guidance in your choice of vendor and service to best match the particular needs of their unique program to complete the IND package. Importantly, when the FDA or EMEA just plain does not like your package, we are here to help you find resolution and get back on the fast track.
OBJECTIVES :
To meet emerging, start-up drug companies, understand the needs of their program and introduce ourselves as a potential resource.
COMPANY INFORMATION :
-
Address :21 Pin Oak Drive Suite 101 - 19460 Phoenixville - Pennsylvania
- Website :http://www.pharmafacts.com
Close
PharmaNet/i3
For intelligent solutions needed to accelerate high quality drug development programs of all sizes around the world, PharmaNet/i3 works for you.
More ?
COMPANY :
PharmaNet/i3, the inVentiv Health clinical segment, is recognized as a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, including therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and staffing from a single clinical professional to an entire functional team.
OBJECTIVES :
PharmaNet/i3 partners with pharmaceutical, biotechnology, generic drug, and medical device companies offering a full range of bioanalytical, Phase I-III clinical trial, regulatory/consulting, and Phase IV post-marketing services.
With a breadth of global resources and expertise in virtually all major therapeutic areas, we have the capacity to conduct any clinical trial, from a single local study to programs spanning multiple continents.
COMPANY INFORMATION :
-
Address :PharmaNet Development Group, Inc. 504 Carnegie Center Princeton, NJ 08540 USA - Princeton - New Jersey
- Website :http://www.pharmanet-i3.com
Close
University of Massachusetts Medical School
UMass is a leading university with over $250 million in funding for medical research.
More ?
COMPANY :
The University of Massachusetts Medical School's Office of Technology Management is committed to promptly and effectively facilitating the commercial development of intellectual property arising at the Medical School, believing that the continued development of innovative research and creative discovery benefits the inventor, the University, the Commonwealth and the world.
OBJECTIVES :
To partner with industry so that University technology can be commercially developed through collaborations and licensing.
COMPANY INFORMATION :
-
Address :Worcester - MA
- Website :http://www.umassmed.edu/
Close
Valens Therapeutics, Inc
Valens Therapeutics is developing novel and unique multi-targeted compounds to address unmet medical needs in neurology, inflammation, oncology, and infectious diseases.
More ?
COMPANY :
Valens Therapeutics is a privately held biopharmaceutical company incorporated in Delaware and headquartered in Baltimore, Maryland, US. The company is developing the next generation of novel multi-targeted compounds to address important unmet medical needs. The company has a proprietary peptide-based platform technology that constitutes its intellectual property. This technology is protected by pending patents covering the peptides, polymer compounds, composition of matter, and methods of use. The company business model is to minimize fixed carrying costs and maximize capital for product development, and to have only a small number of experienced senior executives who select and manage the company projects and contractors.
TECHNOLOGY :
The company’s platform technology was developed by the founder and owner and comprises proprietary molecules that could potentially be developed into drug candidates against several target areas including neurology, inflammation, oncology, ophthalmology, and infectious diseases for which there are no effective treatments. The molecules are target-specific and upon binding to a nano-polymer; we generate novel multi-targeted polymer based compounds with inhibitory, prophylactic, anti-angiogenic and therapeutic activities. The molecules are optimized during synthesis to obtain molecules with suitable physicochemical and biopharmaceutical properties. We have some early lead candidates for neurology, inflammation, oncology, and HIV/AIDS.
OBJECTIVES :
Valens Therapeutics, Inc is seeking an international pharmaceutical partner or European investors or foundations for funding or investment to advance the development of our novel early lead candidates with licensing option for the multi-targeted compound to be developed. We are also interested in a foreign company that wishes to establish a branch in the State of Maryland and joint efforts with our company to develop our lead candidates. Maryland is a friendly State and it is open to foreign companies that wish to come to the US and do investments. We are also interested in networking and meet professionals in the field of neurology and inflammation.
COMPANY INFORMATION :
-
Address :1450 South Rolling Road - 21227 Baltimore - Maryland
- Website :http://www.valenstherapeutics.com
Close